Found: 15
Select item for more details and to access through your institution.
Comparing the rate of immunotherapy treatment change due to toxicity by sex.
- Published in:
- Cancer Reports, 2024, v. 7, n. 2, p. 1, doi. 10.1002/cnr2.1932
- By:
- Publication type:
- Article
First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma.
- Published in:
- Cancer Reports, 2021, v. 4, n. 6, p. 1, doi. 10.1002/cnr2.1419
- By:
- Publication type:
- Article
Mechanisms of Resistance to PD-1 Checkpoint Blockade.
- Published in:
- Drugs, 2020, v. 80, n. 5, p. 459, doi. 10.1007/s40265-020-01270-7
- By:
- Publication type:
- Article
The role of biomarkers in personalized immunotherapy.
- Published in:
- Biomarker Research, 2022, v. 10, n. 1, p. 1, doi. 10.1186/s40364-022-00378-0
- By:
- Publication type:
- Article
Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 18, p. 7637, doi. 10.1002/cam4.2625
- By:
- Publication type:
- Article
A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1229823
- By:
- Publication type:
- Article
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF<sup>V600E</sup> melanoma.
- Published in:
- Science Translational Medicine, 2015, v. 7, n. 279, p. 1, doi. 10.1126/scitranslmed.aaa4691
- By:
- Publication type:
- Article
70. Systemic Administration of siRNA Against EWS-FLI1 Using a Targeted, Non-Viral Formulation Inhibits Growth in a Disseminated Murine Model of Ewing's Sarcoma
- Published in:
- 2005
- By:
- Publication type:
- Abstract
Exosomes as a predictor tool of acquired resistance to melanoma treatment.
- Published in:
- 2014
- By:
- Publication type:
- Abstract
Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 6, p. 773, doi. 10.1007/s11523-021-00833-2
- By:
- Publication type:
- Article
CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Exploring the Landscape of Immune Checkpoint Inhibitor-Induced Adverse Events Through Big Data Mining of Pan-Cancer Clinical Trials.
- Published in:
- Oncologist, 2024, v. 29, n. 5, p. 415, doi. 10.1093/oncolo/oyae012
- By:
- Publication type:
- Article
Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
- Published in:
- BMC Cancer, 2015, v. 15, n. 1, p. 1, doi. 10.1186/s12885-015-1377-8
- By:
- Publication type:
- Article
Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist.
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. 1, doi. 10.1038/s41467-019-12901-3
- By:
- Publication type:
- Article